Announcement • Apr 13
Argent BioPharma Limited (ASX:RGT) completed the acquisition of 48% stake in Cannpal Animal Therapeutics Limited from AusCann Group Holdings Ltd. Argent BioPharma Limited (ASX:RGT) signed a letter of intent to acquire 48% stake in Cannpal Animal Therapeutics Limited from AusCann Group Holdings Ltd for AUD 1.2 million on January 14, 2026. The consideration consists of 20 million common equity of Argent BioPharma Limited to be issued for common equity of Cannpal Animal Therapeutics Limited. As part of consideration, an undisclosed value is paid towards common equity of Cannpal Animal Therapeutics Limited.
The transaction is subject to approval of offer by acquirer shareholders approving the issue of the Consideration Shares. As of April 13, 2026 the transaction has been approved by the acquirer shareholders.
Following completion, Mr Andrew Chapman will join the Board of Argent BioPharma as an Executive Director. Concurrently, Mr Roby Zomer will transition to the role of Non-Executive Chairman, supporting the Company’s next phase of development, including its U.S. national exchange listing strategy and the integration and advancement of the newly acquired assets and advancing potential USA partnership and commercial opportunities.
Argent BioPharma Limited (ASX:RGT) completed the acquisition of 48% stake in Cannpal Animal Therapeutics Limited from AusCann Group Holdings Ltd on April 13, 2026. Announcement • Oct 21
Argent BioPharma Limited, Annual General Meeting, Nov 28, 2025 Argent BioPharma Limited, Annual General Meeting, Nov 28, 2025. Announcement • Apr 03
Argent BioPharma Limited Announces Cannepiltm, Its Cannabinoid-Based Therapy for Refractory Epilepsy, Receives Approval for Prescription in Germany Under Special Access Scheme Argent BioPharma announced that CannEpilTM, its cannabinoid-based therapy for refractory epilepsy, has been approved for prescription in Germany under special access scheme. This approval represents a major milestone in the company's European expansion strategy and reinforces its commitment to providing innovative treatments for central nervous system (CNS) disorders. This achievement marks a significant step in Argent BioPharma's European expansion, strengthening its presence in Germany, a key pharmaceutical hub. Establishing a foothold in this market paves the way for broader penetration into other EU markets with similar regulatory pathways, facilitating wider adoption of Argent's therapies. Beyond geographical growth, this milestone underscores the increasing acceptance of cannabinoid-based medicine for CNS disorders. It positions CannEpilTM as an accessible treatment for refractory epilepsy, offering a vital alternative for patients with limited therapeutic options. Strategically, this progress enhances Argent BioPharma's growth trajectory while reinforcing its leadership in neuroimmune modulation and CNS-focused therapeutics. Most importantly, it ensures life-changing treatment access for patients who need it most, aligning with the company's mission to innovate and expand the reach of medical solutions. Physician Recommendations & Prescription Pathway: CannEpilTM is now available for prescription by qualified physicians in Germany; Patients may be eligible for health insurance coverage depending on their physician's recommendation and case assessment; This approval significantly enhances access for patients with drug-resistant epilepsy. Epilepsy in Germany: Approximately 816,000 people in Germany are diagnosed with epilepsy, with a substantial portion suffering from drug-resistant forms (PMC9480957); Current treatment options remain limited, underscoring the critical need for novel therapeutic approaches; and CannEpilTM offers a promising alternative to traditional treatments, leveraging cannabinoid-based neuroimmune modulation for seizure management. Next Steps: Initiate physician education programs across Germany; Expand CannEpilTM distribution and accessibility through key German partners; Continue regulatory efforts to gain approval in additional EU markets; and Monitor market uptake and patient outcomes to support ongoing research and development. 
